Table 2

Antimicrobial resistance and selected β-lactamase genes identified among BSI E. coli isolates

ST (total no. of isolates)No. (%) of isolates resistant to each classablaCTX-M type(s) (no. of isolates)No. of isolates with:blaKPC type (no. of isolates)
QUINSXTCTXFEPATMCARBblaTEMblaOXA-1
ST131 (51)46 (90)36 (71)17 (33)15 (29)16 (31)0 (0)-15 (13), -1 (3), -14 (2)314
ST95 (40)1 (3)7 (18)1 (3)1 (3)2 (5)0 (0)-14 (1)00-2 (1)
ST73 complex (20)0 (0)7 (35)1 (5)0 (0)1 (5)0 (0)
ST69 (19)2 (11)12 (63)0 (0)0 (0)0 (0)0 (0)
ST12 complex (13)0 (0)9 (69)3 (23)3 (23)3 (23)0 (0)-15 (1b), -14 (2b)30-2 or -3 (1)
ST10 complex (9)1 (11)6 (67)1 (11)1 (11)1 (11)0 (0)-15 (1)10
ST1576 (2)2 (100)0 (0)2 (100)1 (50)2 (100)0 (0)-15 (1), -14 (1)00
ST224 (1)1 (100)1 (100)1 (100)0 (0)1 (100)0 (0)00
ST624 (1)1 (100)1 (100)1 (100)1 (100)1 (100)0 (0)-14 (1)01
ST405 complex (4)1 (25)3 (75)0 (0)0 (0)0 (0)0 (0)
ST998 (1)0 (0)0 (0)1 (100)1 (100)1 (100)0 (0)00
ST964 (1)1 (100)1 (100)0 (0)0 (0)0 (0)0 (0)00
ST38 complex (4)1 (100)4 (100)0 (0)0 (0)0 (0)0 (0)10
Other cluster ST (39)c6 (15)10 (26)1 (3)1 (3)1 (3)0 (0)
Unique ST (15)c0 (0)1 (7)0 (0)0 (0)0 (0)0 (0)
No ST (26)3 (12)10 (38)0 (0)0 (0)0 (0)0 (0)
All (246)66 (27)108 (44)29 (12)24 (10)29 (12)0 (0)26b8152
  • a QUIN, fluoroquinolones; SXT, trimethoprim-sulfamethoxazole; CTX, broad-spectrum cephalosporins (including cefotaxime, ceftazidime, and ceftriaxone); FEP, cefepime; ATM, aztreonam; CARB, carbapenem.

  • b One strain had both blaCTX-M-14 and blaCTX-M-15.

  • c Cluster ST, 2 or more isolates; unique ST, 1 isolate per group.